Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Stage of Development | 9 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Therapy Area | 10 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Indication | 11 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Companies | 14 | 2 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Universities/Institutes | 16 | 2 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Therapeutics Assessment | 18 | 5 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 1 |
| Assessment by Molecule Type | 21 | 2 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Companies Involved in Therapeutics Development | 23 | 10 |
| Amgen Inc. | 23 | 1 |
| AstraZeneca Plc | 24 | 1 |
| Bristol-Myers Squibb Company | 25 | 1 |
| Eisai Co., Ltd. | 26 | 1 |
| Eli Lilly and Company | 27 | 1 |
| Genentech, Inc. | 28 | 1 |
| Johnson &Johnson | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| Novartis AG | 31 | 1 |
| Vitae Pharmaceuticals, Inc. | 32 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Drug Profiles | 33 | 26 |
| AMG-8718 Drug Profile | 33 | 1 |
| AVCRI-104P3 Drug Profile | 34 | 1 |
| AVCRI-175P1 Drug Profile | 35 | 1 |
| AZ-4217 Drug Profile | 36 | 1 |
| AZD-3293 Drug Profile | 37 | 2 |
| CNP-520 Drug Profile | 39 | 1 |
| E-2609 Drug Profile | 40 | 2 |
| ER-901356 Drug Profile | 42 | 1 |
| GNE-892 Drug Profile | 43 | 1 |
| JNJ-54861911 Drug Profile | 44 | 2 |
| LY-2811376 + LY-3002813 Drug Profile | 46 | 1 |
| LY-3202626 Drug Profile | 47 | 1 |
| Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease Drug Profile | 48 | 1 |
| Small Molecule to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease Drug Profile | 49 | 1 |
| Small Molecule to Inhibit BACE 1 for Alzheimer s Disease Drug Profile | 50 | 1 |
| Small Molecule to Inhibit BACE1 for Alzheimer's Disease Drug Profile | 51 | 1 |
| Small Molecule to Inhibit BACE1 for Alzheimer s Disease Drug Profile | 52 | 1 |
| Small Molecules to Inhibit BACE1 for Alzheimer Disease Drug Profile | 53 | 1 |
| Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease Drug Profile | 54 | 1 |
| TAK-070 Drug Profile | 55 | 1 |
| verubecestat Drug Profile | 56 | 2 |
| VTP-36951 Drug Profile | 58 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Dormant Projects | 59 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Discontinued Products | 60 | 1 |
| Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Featured News &Press Releases | 61 | 11 |
| Jun 14, 2016: New Alzheimer s Study Aimed at Preventing or Delaying Symptoms | 61 | 1 |
| Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer s disease | 62 | 1 |
| Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer s Disease | 63 | 1 |
| Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer s disease | 63 | 1 |
| May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug | 64 | 1 |
| Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer s Disease Therapy, MK-8931 | 64 | 1 |
| Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer s Disease | 65 | 1 |
| Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research | 66 | 1 |
| Dec 03, 2012: Merck Initiates Phase II/III Study of Investigational BACE Inhibitor MK-8931 For Treatment Of Alzheimer's Disease | 67 | 1 |
| Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2012 | 67 | 1 |
| Jul 13, 2012: Eisai To Present First Clinical Data For Bace Inhibitor E2609 At Alzheimer's Association International Conference 2012 | 68 | 1 |
| Jun 08, 2012: Takeda Announces Transfer Of TAK-070 To National University Corporation | 69 | 1 |
| Apr 27, 2012: Merck Presents Results Of Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology | 70 | 1 |
| Feb 09, 2009: Ligand Earns $1 Million Milestone Payment On Progress Of Drug Candidate For Alzheimer's Disease | 70 | 2 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |